Metaxalone

Summary

Metaxalone (CHEMBL1079604) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 4
• Chemistry: 221.25 Da · C12H15NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1079604
Name	Metaxalone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	15459
Molecular formula	C12H15NO3
Molecular weight	221.25
InChIKey	IMWZZHHPURKASS-UHFFFAOYSA-N

SMILES: CC1=CC(=CC(=C1)OCC2CNC(=O)O2)C

IUPAC name: 5-[(3,5-dimethylphenoxy)methyl]-1,3-oxazolidin-2-one

Also known as: AHR-438, Flexura, Metaxalona, Metaxalone, NSC-170959, Skelaxin, Zorane, SID26748938, METAXALONE, SID144204981, SID170465241, metaxalone

Patent coverage: 1,395 distinct patent families (5,021 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Prelamin-A/C, Amine oxidase [flavin-containing] A, Sodium-dependent noradrenaline transporter.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	3
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06484192	PHASE4	ENROLLING_BY_INVITATION	Pain Control After Lumbar Spine Fusion
NCT03068897	PHASE4	COMPLETED	Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain
NCT06382662	PHASE4	COMPLETED	Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition
NCT04003350	Not specified	COMPLETED	The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).